{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T06:45:22Z","timestamp":1769064322284,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:00:00Z","timestamp":1647129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Acquired haemophilia A (AHA) is a rare bleeding disorder caused by development of auto\u2010antibodies to endogenous coagulation factor VIII (FVIII). Recombinant porcine factor VIII (rpFVIII) is currently licensed only for the management of bleeding in patients with AHA. Regular monitoring of rpFVIII is recommended to assess treatment effectiveness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>This guideline from the United Kingdom Haemophilia Centre Doctors\u2019 Organisation (UKHCDO) examines the current publications in the area and aims to offer advice for the laboratory monitoring of rpFVIII in patients with AHA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A review of the current literature was undertaken followed by critical review by the authors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results\/conclusions<\/jats:title><jats:p>A validated one\u2010stage clotting FVIII assay is recommended for the measurement and regular monitoring of rpFVIII. Assessment of cross\u2010reacting rpFVIII inhibitors by one\u2010stage porcine Bethesda assay should be performed as part of the initial diagnosis of AHA or prior to treatment with rpFVIII. Available data show that chromogenic FVIII assays underestimate rpFVIII and this should be considered if measurement of rpFVIII is required in patients receiving Emicizumab.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14536","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T09:25:35Z","timestamp":1647163535000},"page":"515-519","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Laboratory coagulation tests and recombinant porcine factor VIII: A United Kingdom Haemophilia Centre Doctors\u2019 Organisation guideline"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-5848","authenticated-orcid":false,"given":"Annette","family":"Bowyer","sequence":"first","affiliation":[{"name":"Department of Coagulation Royal Hallamshire Hospital  Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-1256","authenticated-orcid":false,"given":"Elaine","family":"Gray","sequence":"additional","affiliation":[{"name":"Haemostasis Section National Institute for Biological Standards and Control  Potters Bar UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2492-4438","authenticated-orcid":false,"given":"Anna","family":"Lowe","sequence":"additional","affiliation":[{"name":"UK National External Quality Assurance Scheme for Blood Coagulation  Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Murphy","sequence":"additional","affiliation":[{"name":"Department of Haematology Newcastle Upon Tyne Hospitals  Newcastle upon Tyne UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5466-0448","authenticated-orcid":false,"given":"Sean","family":"Platton","sequence":"additional","affiliation":[{"name":"The Royal London Hospital Haemophilia Centre Barts Health NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6594-5353","authenticated-orcid":false,"given":"Anne","family":"Riddell","sequence":"additional","affiliation":[{"name":"Katharine Dormandy Haemophilia Centre Royal Free Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6690-8586","authenticated-orcid":false,"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[{"name":"Katharine Dormandy Haemophilia Centre Royal Free Hospital  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8790-7112","authenticated-orcid":false,"given":"Will","family":"Lester","sequence":"additional","affiliation":[{"name":"Haemophilia Unit University Hospitals Birmingham  Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5301-464X","authenticated-orcid":false,"given":"Peter Vincent","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Haematology Department University Hospital of Wales  Cardiff UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,3,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.1.31.31"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.6.1513.1513"},{"key":"e_1_2_6_4_1","first-page":"365","article-title":"Porcine recombinant factor VIII: an additional weapon to handle anti\u2010factor VIII antibodies","volume":"15","author":"Mannucci PM","year":"2017","journal-title":"Blood Transfus"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1989.00390060103022"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02803.x"},{"key":"e_1_2_6_7_1","unstructured":"EMA.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/obizur\u2010epar\u2010product\u2010information_en.pdf202116\/05\/2021. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/obizur\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13157"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13495"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02523.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13907"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02789.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620717720861"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12627"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13426"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13001"},{"key":"e_1_2_6_18_1","article-title":"FVIII assay and APTT results on Obizur in\u2010vitro spiked plasma samples: analysis from the first UK National External Quality Assurance Scheme for Blood Coagulation (UK NEQAS BC) Obizur Exercise [abstract]","volume":"4","author":"Lowe AE","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00130.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13108"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13990"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20390"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-0734.2001.00049.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1027-y"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14618"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14162"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16556"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13644"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13040"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9026121"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002977"},{"key":"e_1_2_6_32_1","first-page":"312","article-title":"Susoctocog\u2010alfa (Obizur\u00ae) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real world experience","volume":"18","author":"Zanon E","year":"2020","journal-title":"Blood Transfus"},{"key":"e_1_2_6_33_1","first-page":"105","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","author":"Tiede A","year":"2020","journal-title":"Haematologica"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13903"},{"key":"e_1_2_6_35_1","first-page":"362","article-title":"Validation of a FVIII Nijmegen Bethesda assay for the detection of inhibitors to porcine FVIII","volume":"1","author":"Robinson M","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_2_6_36_1","first-page":"247","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"72","author":"Verbruggen B","year":"1995","journal-title":"Throm Haemost"},{"key":"e_1_2_6_37_1","unstructured":"NEQAS.UK NEQAS for Blood Coagulation: FVIII inhibitor\/emicizumab supplementary exercise participants report. Personal communication ed: UK NEQAS for Blood Coagulation;2019:1\u20135."}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14536","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hae.14536","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14536","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T10:38:10Z","timestamp":1692959890000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,13]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1111\/hae.14536"],"URL":"https:\/\/doi.org\/10.1111\/hae.14536","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,13]]},"assertion":[{"value":"2021-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}